Mather Group LLC. Increases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Mather Group LLC. raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 55.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,070 shares of the medical research company’s stock after acquiring an additional 1,811 shares during the period. Mather Group LLC.’s holdings in Edwards Lifesciences were worth $484,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Edwards Lifesciences by 1.1% during the first quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after acquiring an additional 600,994 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Edwards Lifesciences by 9.5% in the first quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock worth $1,813,089,000 after buying an additional 1,644,869 shares during the period. Brown Advisory Inc. boosted its position in shares of Edwards Lifesciences by 20.1% in the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after buying an additional 3,048,274 shares during the period. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 2.4% in the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock worth $1,283,098,000 after buying an additional 393,109 shares during the period. Finally, Norges Bank purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $648,540,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $1.23 during trading on Tuesday, reaching $61.93. The company’s stock had a trading volume of 6,925,647 shares, compared to its average volume of 3,975,926. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The business’s fifty day moving average price is $84.78 and its 200-day moving average price is $86.49. The firm has a market cap of $37.31 billion, a price-to-earnings ratio of 26.69, a price-to-earnings-growth ratio of 2.57 and a beta of 1.11. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.66 earnings per share. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. Oppenheimer cut their price target on Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating on the stock in a research note on Thursday, July 25th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft dropped their price target on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Finally, StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $82.10.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $87.81, for a total transaction of $439,050.00. Following the transaction, the vice president now directly owns 47,750 shares in the company, valued at $4,192,927.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $87.81, for a total transaction of $439,050.00. Following the sale, the vice president now directly owns 47,750 shares of the company’s stock, valued at $4,192,927.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 5,625 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $90.45, for a total value of $508,781.25. Following the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,764,242.45. The disclosure for this sale can be found here. Insiders have sold 29,242 shares of company stock worth $2,607,520 over the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.